Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ADC Therapeutics SA stock logo
ADCT
ADC Therapeutics
$3.01
+4.7%
$2.55
$1.05
$4.13
$298.73M1.89595,665 shs222,290 shs
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
$4.48
-1.1%
$4.30
$3.62
$9.18
$32.75M0.651,859 shs2,490 shs
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
$2.02
-3.6%
$1.74
$0.77
$2.27
$201.06M2.311.74 million shs793,925 shs
Theratechnologies Inc. stock logo
THTX
Theratechnologies
$3.15
+0.2%
$2.62
$1.12
$3.20
$144.61M0.55885,233 shs474,167 shs
7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ADC Therapeutics SA stock logo
ADCT
ADC Therapeutics
+5.93%+5.93%-22.28%+135.39%-6.54%
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
-0.44%+2.95%+2.95%+10.49%-17.21%
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
-3.69%+0.48%+29.81%+86.61%+77.87%
Theratechnologies Inc. stock logo
THTX
Theratechnologies
-0.95%+36.52%+21.71%+121.13%+125.90%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
ADC Therapeutics SA stock logo
ADCT
ADC Therapeutics
1.5241 of 5 stars
3.52.00.00.00.00.80.6
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
4.0147 of 5 stars
3.23.00.04.60.62.50.6
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
0.1221 of 5 stars
0.01.00.00.00.01.70.6
Theratechnologies Inc. stock logo
THTX
Theratechnologies
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ADC Therapeutics SA stock logo
ADCT
ADC Therapeutics
3.00
Buy$7.75170.98% Upside
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
2.33
Hold$39.50771.96% Upside
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
0.00
N/AN/AN/A
Theratechnologies Inc. stock logo
THTX
Theratechnologies
3.00
BuyN/AN/A

Current Analyst Ratings Breakdown

Latest KZR, ADCT, THTX, and SLS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/3/2025
Theratechnologies Inc. stock logo
THTX
Theratechnologies
Jones Trading
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
6/20/2025
ADC Therapeutics SA stock logo
ADCT
ADC Therapeutics
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeOutperform ➝ Moderate Buy$8.00 ➝ $5.00
6/13/2025
ADC Therapeutics SA stock logo
ADCT
ADC Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$7.00 ➝ $10.00
5/15/2025
ADC Therapeutics SA stock logo
ADCT
ADC Therapeutics
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$8.00 ➝ $8.00
4/11/2025
Theratechnologies Inc. stock logo
THTX
Theratechnologies
Jones Trading
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
(Data available from 7/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ADC Therapeutics SA stock logo
ADCT
ADC Therapeutics
$70.84M4.00N/AN/A($2.10) per share-1.36
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
$7M4.73N/AN/A$16.02 per share0.28
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
$1M208.54N/AN/A$0.13 per share16.08
Theratechnologies Inc. stock logo
THTX
Theratechnologies
$85.87M1.68N/AN/A($0.55) per share-5.71
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ADC Therapeutics SA stock logo
ADCT
ADC Therapeutics
-$157.85M-$1.45N/AN/AN/A-197.64%N/A-45.57%8/5/2025 (Estimated)
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
-$83.74M-$10.82N/AN/AN/AN/A-61.15%-50.27%8/12/2025 (Estimated)
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
-$30.88M-$0.38N/AN/AN/AN/A-193.67%-113.02%8/12/2025 (Estimated)
Theratechnologies Inc. stock logo
THTX
Theratechnologies
-$8.31M-$0.08N/A44.86N/A-4.18%N/A-0.37%7/9/2025 (Estimated)

Latest KZR, ADCT, THTX, and SLS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2025Q2 2025
ADC Therapeutics SA stock logo
ADCT
ADC Therapeutics
-$0.36N/AN/AN/A$17.82 millionN/A
5/14/2025Q1 2025
ADC Therapeutics SA stock logo
ADCT
ADC Therapeutics
-$0.38-$0.36+$0.02-$0.36$17.71 million$23.03 million
5/13/2025Q1 2025
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
-$2.56-$2.27+$0.29-$2.27N/AN/A
5/13/2025Q1 2025
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
-$0.1067-$0.07+$0.0367-$0.07N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
ADC Therapeutics SA stock logo
ADCT
ADC Therapeutics
N/AN/AN/AN/AN/A
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
N/AN/AN/AN/AN/A
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
N/AN/AN/AN/AN/A
Theratechnologies Inc. stock logo
THTX
Theratechnologies
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ADC Therapeutics SA stock logo
ADCT
ADC Therapeutics
N/A
4.46
4.16
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
0.04
7.09
7.09
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
N/A
4.64
4.64
Theratechnologies Inc. stock logo
THTX
Theratechnologies
N/A
1.08
0.88

Institutional Ownership

CompanyInstitutional Ownership
ADC Therapeutics SA stock logo
ADCT
ADC Therapeutics
41.10%
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
67.90%
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
17.38%
Theratechnologies Inc. stock logo
THTX
Theratechnologies
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
ADC Therapeutics SA stock logo
ADCT
ADC Therapeutics
31099.18 million93.82 millionOptionable
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
607.31 million6.63 millionNot Optionable
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
1099.78 million98.58 millionNot Optionable
Theratechnologies Inc. stock logo
THTX
Theratechnologies
14045.98 millionN/AOptionable

Recent News About These Companies

Future Pak to buy Theratechnologies for $254 million
Theratechnologies Inc. (THTX) - Yahoo Finance
Theratechnologies to further evaluate potential sale of the company

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADC Therapeutics stock logo

ADC Therapeutics NYSE:ADCT

$3.01 +0.14 (+4.74%)
As of 10:51 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

Kezar Life Sciences stock logo

Kezar Life Sciences NASDAQ:KZR

$4.48 -0.05 (-1.10%)
As of 10:51 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

SELLAS Life Sciences Group stock logo

SELLAS Life Sciences Group NASDAQ:SLS

$2.02 -0.08 (-3.59%)
As of 10:51 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

Theratechnologies stock logo

Theratechnologies NASDAQ:THTX

$3.14 +0.01 (+0.16%)
As of 10:51 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen. Its pipeline products include F8 Formulation that is in Phase 2b/3 clinical trials for studying tesamorelin for the treatment of nonalcoholic steatohepatitis; multi -dose pen injector for the administration of tesamorelin; SORT1+ Technology Platform for the development of proprietary peptides for cancer drug development targeting SORT1 receptors; Sudocetaxel Zendusortide, which is in Phase 1 Clinical Trial for various solid tumor types, including HR+ breast, triple negative breast, ovarian, endometrial, melanoma, thyroid, small cell lung, and prostate cancers. The company was incorporated in 1993 and is headquartered in Montreal, Canada.